4-AP (Fampridine-SR) passes FDA heart test
Posted: Mon Jan 28, 2008 4:38 pm
<shortened url>
Acorda Therapeutics (nasdaq: ACOR - news - people ) said its multiple sclerosis drug Fampridine-SR does not raise the risk of heart-related side effects anymore than a placebo in a so-called QT cardiac safety study required by the U.S. Food and Drug Administration. Acorda shares were up 20.1%, or $4.38, at $26.16, in afternoon trading.
Acorda Therapeutics (nasdaq: ACOR - news - people ) said its multiple sclerosis drug Fampridine-SR does not raise the risk of heart-related side effects anymore than a placebo in a so-called QT cardiac safety study required by the U.S. Food and Drug Administration. Acorda shares were up 20.1%, or $4.38, at $26.16, in afternoon trading.